Evestra, Inc.

Bindu Santhamma

Klaus Nickisch

Hareesh Nair

Walter Elger

Ralf Wyrwa

Kesavaram Narkunan

Gulzar Ahmed

Frederick Meece

Kirk Acosta

Baishakhi Debnath

Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.

Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

Various prodrug compounds having the general structure: Active agent&#x2014;(acid)-(linker)&#x2014;SONRRare described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Pro-drug forming compounds

Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.

Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer

Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SONRRare described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.

Imidazolyl progesterone antagonists

Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.

Growing community of inventors

San Antonio, TX, United States of America

Bindu Santhamma